Late-onset Tay-Sachs disease

Israel Medical Association Journal

Volumn 6, Issue 2, 2004, Pages 107-111

  Neudorfer, Orit ^a   Kolodny, Edwin H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GM2 gangliosidosi; Glycosphingolipid; Hexosaminidase A; Lysosomal storage disease; Tay Sachs disease

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE B; CARBAMAZEPINE; ENZYME; GANGLIOSIDE GM2; LITHIUM SALT; LORAZEPAM; MIGLUSTAT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLIGOSACCHARIDE; RETROVIRUS VECTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

BIOCHEMISTRY; BONE MARROW TRANSPLANTATION; CATATONIA; CLINICAL FEATURE; CLINICAL TRIAL; DYSARTHRIA; ELECTROCONVULSIVE THERAPY; ENZYME REPLACEMENT; EXERCISE; EXTRAPYRAMIDAL SYNDROME; GENE MUTATION; GENE THERAPY; GENETICS; HUMAN; MENTAL DISEASE; MOLECULAR GENETICS; MOOD DISORDER; MUTATION; NONHUMAN; ONSET AGE; PSYCHOSIS; REVIEW; SIDE EFFECT; SPEECH THERAPY; STEM CELL TRANSPLANTATION; TAY SACHS DISEASE;

AGE OF ONSET; BETA-N-ACETYLHEXOSAMINIDASE; BONE MARROW TRANSPLANTATION; GENE THERAPY; HUMANS; MUTATION; TAY-SACHS DISEASE;

EID: 1142291623     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Tay W. Symmetrical changes in the region of the yellow spot in each eye of an infant. Trans Ophthalmol Soc UK 1881;1:55.
2. Sachs B. On arrested cerebral development with special reference to its cortical pathology. J Nerv Ment Dis 1887;14:541.
3. Navon R, Argov Z, Frisch A. Hexosaminidase A deficiency in adults. Am J Hum Genet 1986;24:179-96.
4. M2 gangliosidosis. Br J Psychiatr 1989;155:410-13.
5. MacQueen GM, Rosebush PI, Mazurek MF. Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. J Neuropsychiatry Clin Neurosci 1998;10:10-19.
6. M2 gangliosidosis. A case report. Br J Psychiatry 1988;153:387.
7. Harding AE, Young EP, Schon F. Adult onset supranuclear ophthalmoplegia, cerebellar ataxia, and neurogenic proximal muscle weakness in a brother and sister: Another hexosaminidase A deficiency syndrome. J Neurol Neurosurg Psychiatry 1987;50:687.
8. M2 gangliosidosis. Neurology 1993;43:2055-8.
9. M2 gangliosidosis, seizures, dementia, and normal pressure hydrocephalis associated with glycolipid storage in the brain and arachnoid granulations. Neurology 1978;28:1117-23.
10. M2 gangliosidosis: Case report and review of the literature. Eur Neurol 1986;25:154-9.
11. M2-gangliosidosis masquerading as slowly progressive muscular atrophy: Motor neuron disease phenotype. Clin Neuropathol 1982;1:31-44.
12. Sonderfeld-Fresko S, Proia RL. Synthesis and assembly of a catalytically active lysosomal enzyme, β-hexosaminidase B, in a cell-free system. J Biol Chem 1988;263:13463-9.
13. Takeda K, Nakai H, Hagiwara H, et al. Fine assignment of β-hexosaminidase A α-subunit on 15q23-q24 by high resolution in situ hybridization. Tohoku J Exp Med 1990;160:203-11.
14. M2-activator locus. Neurology 1991;41:1418-22.
15. M2 gangliosidoses in patients of Ashkenazi Jewish origin: Substitution of serine for glycine at position 269 of the α-subunit of β-hexosaminidase. Proc Natl Acad Sci USA 1989;86:2413-17.
16. M2 gangliosidosis patients share a common genetic defect. Am J Hum Genet 1990;46:817-21.
17. Akli S, Chelly J, Kahn A, Poenaru L. A null allele frequent in non-Jewish Tay-Sachs patients. Hum Genet 1993;90:614-20.
18. Cordeiro P, Hechtman P, Kaplan F. The GM2 gangliosidoses databases: Allelic variation at the HEXA, HEXB, and GM2A gene loci. Genet Med 2000;2:319-27.
19. Taniike M, Yamanaka S, Proia RL, Langaman C, Bone-Turrentine T, Suzuki K. Neuropathology of mice with targeted description of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathologica 1995;89:296-304.
20. Kolodny EH, Brady RO, Volk BW. Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease. Biochem Biophys Res Commun 1969;37(3):526-31.
21. Jeyakumar M, Smith D, Eliott-Smith E, et al. An inducible mouse model of late onset tay-sachs disease. Neurobiol Dis 2002;10(3):201-10.
22. Manor I, Hermesh H, Munitz H, Weizman A. Neuroleptic malignant syndrome with gangliosidosis type II. Biol Psychiatry 1997;41(12):1222-4.
23. Filho JAF, Friedman SH, Kyle EA, Shapiro B. Medication survey in patients with hexosaminidase A deficiency: Implications for treatment. Neurology 2003;60(Suppl 1):A52.
24. Norflus F, Tifft CJ, McDonald MP, et al. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest 1998;101(9):1881-8.
25. Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 2000;97(20):10954-9.
26. Oya Y, Proia RL, Norflus F, Tifft CJ, Langaman C, Suzuki K. Distribution of enzyme-bearing cells in GM2 gangliosidosis mice: Regionally specific pattern of cellular infiltration following bone marrow transplantation. Acta Neuropathol (Berl) 2000;99(2):161-8.
27. Flax JD, Aurora S, Yang C, et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 1998;16(11):1033-9.
28. Johnson W, Desnick R, Long D, Sharp M, Krivit W, Brady R. Intravenouse injection of purified Hexosaminidase A into patients with Tay-Sachs disease. In: Desnick R, Bernlohr R, Krivit W, eds: Enzyme Therapy in Genetic Diseases. New York: Alan R Liss, 1973:120.
29. von Sprecht BU, Geiger B, Arnon R, et al. Enzyme replacement in Tay-Sachs disease. Neurology 1979;29(6):848-54
30. Teixeira CA, Sena-Esteves M, Lopes L, Sa Miranda MC, Ribeiro MG. Retrovirus-mediated transfer and expression of beta-hexosaminidase alpha-chain cDNA in human fibroblasts from G(M2)-gangliosidosis B1 variant. Hum Gene Ther 2001;12(14):1771-83.
31. Guidotti J, Akli S, Castelnau-Ptakhine L, Kahn A, Poenaru L. Retrovirus-mediated enzymatic correction of Tay-Sachs defect in transduced and non-transduced cells. Hum Mol Genet 1998;7(5):831-8.
32. Martino C, Emiliani C, Tancini B, et al. Absence of metabolic cross-correction in Tay-Sachs cells: Implications for gene therapy. J Biol Chem 2002;277(23):20177-84.
33. Guidotti JE, Mignon A, Haase G, et al. Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice. Hum Mol Genet 1999;8(5):831-8.
34. Liu Y, Wada R, Kawai H, et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest 1999;103(4):497-505.
35. Platt FM, Neises GR, Reinkensmeir G, et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 1997;276(5311):428-31.
36. Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 1999;96(11):6388-93.
37. Jeyakumar M, Norflus F, Tift CJ, et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 2001;97(1):327-9.